![Gary Dubin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gary Dubin formerly worked at HilleVax, Inc., as Independent Director from 2022 to 2025, Takeda Pharmaceuticals U.S.A., Inc., as President-Vaccine Business, GlaxoSmithKline Vaccines Srl, as VP & Head-Late Clinical Development from 2010 to 2015, and the University of Pennsylvania, as Assistant Professor.
Dr. Dubin received his doctorate degree from the University of Pennsylvania.
| Companies | Position | End |
|---|---|---|
| HILLEVAX, INC. | Director/Board Member | 17/09/2025 |
Glaxosmithkline Vaccines Srl
 Glaxosmithkline Vaccines Srl BiotechnologyHealth Technology Develops, manufactures and distributes vaccines | Corporate Officer/Principal | 01/01/2015 |
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Corporate Officer/Principal | - |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
| Private companies | 4 |
|---|---|
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Glaxosmithkline Vaccines Srl
Glaxosmithkline Vaccines Srl BiotechnologyHealth Technology Develops, manufactures and distributes vaccines | Health Technology |
HilleVax, Inc.
 HilleVax, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in the development and commercialization of novel vaccine candidates | Health Technology |
Select your edition
All financial news and data tailored to specific country editions
